Read up on our latest news

Featured Story

Mirvie Founders
Mirvie Raises $60 Million For Blood Test To Predict Pregnancy Complications
May 17, 2022
The company announced it raised $60 million in Series B funding led by Decheng Capital. BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield participated in the round. Olympic runner Allyson Felix, whose daughter was born eight weeks early due to preeclampsia complications, also invested in the round. The company has raised a total of $90 million to date.
Read more
Stst Logo
Mirvie Raises $60 Million For Blood Test To Predict Pregnancy Complications
May 17, 2022
The company announced it raised $60 million in Series B funding led by Decheng Capital. BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield participated in the round. Olympic runner Allyson Felix, whose daughter was born eight weeks early due to preeclampsia complications, also invested in the round. The company has raised a total of $90 million to date.
Read more
Mirvie Founders

Media Coverage

press logo
RNA-based blood test detects severe preeclampsia in mid-pregnancy
April 10, 2025
Research led by Mirvie Inc. has discovered a molecular signal in blood samples that can predict preeclampsia and related conditions months before clinical symptoms appear.
Read more
press logo
Mirvie reveals new advances in the biological understanding of hypertensive disorders of pregnancy
April 9, 2025
Mirvie's preeclampsia risk prediction test can now improve risk assessment, helping women and their care teams be informed and take actions with the potential to delay onset or prevent the disease.
Read more
press logo
Mom, 32, had a life-threatening pregnancy complication. Doctors dismissed the signs for weeks
May 23, 2024
Mirvie is developing a test to predict preeclampsia risk by looking at changes in the blood. Better testing will help more people be diagnosed earlier and also could help experts develop better treatments for it.
Read more
press logo
Preeclampsia Subtypes Uncovered in Large Mirvie Study
April 9, 2025
Research from a study including more than 9,000 women, led by pregnancy diagnostics biotech Mirvie, has uncovered distinct subtypes of blood pressure–related disorders of pregnancy including preeclampsia.
Read more
press logo
Breakthrough study backs Mirvie blood test to predict preeclampsia months before symptoms
April 8, 2025
Results from a breakthrough study published today in Nature Communications reveal new advances in the biological understanding of hypertensive disorders of pregnancy (HDP), including preeclampsia
Read more
press logo
Research advances biological understanding of hypertensive disorders of pregnancy
April 8, 2025
Diagnostics company Mirvie has announced the results of a breakthrough study that reveals new advances in the biological understanding of hypertensive disorders of pregnancy (HDP), including preeclampsia – a leading cause of maternal morbidity and mortality as well as preterm birth.
Read more
press logo
Mirvie Validates Blood Test to Predict Preeclampsia Months Before Symptoms
April 8, 2025
The validation results show the blood test can identify 91% of pregnancies that will develop preterm preeclampsia in women aged 35+ without pre-existing high-risk conditions, months ahead of symptoms.
Read more
press logo
How science is individualizing pregnancy risks
March 10, 2025
Each pregnancy has its own unique biology that can power personalized care.
Read more
press logo
Mirvie's RNA platform revolutionizes detection of fetal growth restriction
February 4, 2025
Discover how Mirvie’s RNA platform uses a simple blood test to detect fetal growth restriction early in pregnancy, allowing for proactive interventions and improved outcomes for mothers and babies.
Read more
press logo
Mirvie’s RNA Platform Shows Promise in Predicting Severe Fetal Growth Restriction
January 31, 2025
Mirvie has announced new research demonstrating its RNA platform’s ability to predict severe fetal growth restriction months before delivery
Read more
A personalized window
into pregnancy health.
650-741-6510
651 Gateway Boulevard, Suite 1200
South San Francisco, California 94080
References
Terms of Service
Privacy Policy
©2025 Mirvie, Inc. All rights reserved.